Publicacions en què col·labora amb Ángel Plácido LLaneza Coto (25)

2024

  1. Eligibility criteria for using menopausal hormone therapy in breast cancer survivors: a safety report based on a systematic review and meta-analysis

    Menopause (New York, N.Y.), Vol. 31, Núm. 3, pp. 234-242

2023

  1. Associations between Menopausal Hormone Therapy and Colorectal, Lung, or Melanoma Cancer Recurrence and Mortality: A Narrative Review

    Journal of Clinical Medicine, Vol. 12, Núm. 16

  2. Population-based survey on menopausal symptoms and treatment use

    Climacteric, Vol. 26, Núm. 1, pp. 47-54

2022

  1. Eligibility criteria for Menopausal Hormone Therapy (MHT): a position statement from a consortium of scientific societies for the use of MHT in women with medical conditions. MHT Eligibility Criteria Group

    Maturitas, Vol. 166, pp. 65-85

2021

  1. Health-related quality of life and resilience in peri- and postmenopausal women during Covid-19 confinement

    Maturitas, Vol. 144, pp. 4-10

  2. Predictive and criterion validity of the Cervantes-SF menopause quality of life questionnaire

    Menopause (New York, N.Y.), Vol. 28, Núm. 8, pp. 935-942

  3. Women's knowledge about the genitourinary syndrome of menopause: adherence to its treatments in the COVID-19 era in a sample of them: COMEM-GSM study

    BMC Women's Health, Vol. 21, Núm. 1

2020

  1. Beliefs, knowledge and the impact of COVID19 on menopause therapies in Spanish women: COMEM-treatment study

    BMC Women's Health, Vol. 20, Núm. 1

  2. Managing thromboembolic risk with menopausal hormone therapy and hormonal contraception in the COVID-19 pandemic: Recommendations from the Spanish Menopause Society, Sociedad Española de Ginecología y Obstetricia and Sociedad Española de Trombosis y Hemostasia

    Maturitas, Vol. 137, pp. 57-62

  3. Response to “Should estrogen be used in the co-treatment of COVID-19 patients?”

    Maturitas

  4. The thromboembolic risk in covid-19 women under hormonal treatment group

    Maturitas

2019

  1. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial

    Gynecological Endocrinology, Vol. 35, Núm. 8, pp. 695-700

2018

  1. Aeem-sego position statement on menopausal hormone therapy

    Progresos de Obstetricia y Ginecologia, Vol. 61, Núm. 3, pp. 230-234

  2. What do TSECs provide in the menopausal hormone therapy?

    Gynecological Endocrinology, Vol. 34, Núm. 10, pp. 826-832

2017

  1. Recommendations of the Spanish Menopause Society on the consumption of omega-3 polyunsaturated fatty acids by postmenopausal women

    Maturitas, Vol. 103, pp. 71-77

  2. Sexual health in Spanish postmenopausal women presenting at outpatient clinics

    Climacteric, Vol. 20, Núm. 2, pp. 164-170

2016

  1. Benefits of physical exercise in postmenopausal women

    Maturitas, Vol. 93, pp. 83-88

  2. Factors determining the use of hormonal therapy and phytotherapy in Spanish postmenopausal women

    Climacteric, Vol. 19, Núm. 4, pp. 375-380

2015

  1. A prospective study of DT56a (Femarelle®) for the treatment of menopause symptoms

    Climacteric, Vol. 18, Núm. 6, pp. 813-816

  2. Effectiveness and efficiency of cervical screening in older women

    Maturitas